Quadient Accelerates Growth of Cloud-based Solutions in the 15-03-2023, 15:29

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Brandon Hall Group Launches Study on Evolution of Skills 13-02-2023, 22:03